Tivic Health names Michael Handley COO and President of Tivic Biopharma following Statera license

Valion Bio, Inc.

Handley appointed COO and President of new Tivic Biopharma division, effective Feb 18, 2025.
Compensation: $300k base salary, up to 35% bonus, 600k RSUs vesting over 4 years.
Handley previously CEO of Statera Biopharma; helped commercialize 17 drugs/devices worth ~$7B in sales.
Role includes advancing late-stage Entolimod (TLR5 agonist) for radiation protection and immune indications.
Appointment follows Feb 11 exclusive license of Entolimod from Statera, previously disclosed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Handley

Chief Operating Officer and President of Tivic Biopharma division

VBIO · Valion Bio, Inc.

Effective: 2025-02-18
Filed: February 24, 2025, 6:59 PM ET

On February 18, 2025, Michael Handley was appointed as Chief Operating Officer of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), and President of the Company’s Tivic Biopharma division.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Handley was appointed as Chief Operating Officer and President of Tivic Biopharma division at Valion Bio, Inc..

Action: appointed
Role: Chief Operating Officer and President of Tivic Biopharma division

Exact text from the filing

On February 18, 2025, Michael Handley was appointed as Chief Operating Officer of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), and President of the Company’s Tivic Biopharma division.

View on SEC.gov

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-025238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.